The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-28
DOI
10.1007/s00228-020-02947-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China
- (2020) Dawei Wang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The neuroinvasive potential of SARS‐CoV2 may be at least partially responsible for the respiratory failure of COVID‐19 patients
- (2020) Yan‐Chao Li et al. JOURNAL OF MEDICAL VIROLOGY
- Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
- (2020) Nanshan Chen et al. LANCET
- Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study
- (2020) Heshui Shi et al. LANCET INFECTIOUS DISEASES
- Clinical Characteristics of Coronavirus Disease 2019 in China
- (2020) Wei-jie Guan et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Novel Coronavirus from Patients with Pneumonia in China, 2019
- (2020) Na Zhu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
- (2020) Athol U Wells et al. Lancet Respiratory Medicine
- Coronavirus Disease 2019 (COVID-19) in Italy
- (2020) Edward Livingston et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pirfenidone exerts beneficial effects in patients with IPF undergoing single lung transplantation
- (2019) Tobias Veit et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial
- (2019) Toby M Maher et al. Lancet Respiratory Medicine
- Pirfenidone for the treatment of idiopathic pulmonary fibrosis
- (2017) Peter M George et al. Expert Review of Clinical Pharmacology
- Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities
- (2017) Christopher S King et al. Lancet Respiratory Medicine
- Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis
- (2017) Steven D Nathan et al. Lancet Respiratory Medicine
- The evolving pharmacotherapy of pulmonary fibrosis
- (2012) Harpreet K Lota et al. EXPERT OPINION ON PHARMACOTHERAPY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started